Company intelligence / Profile preview

Antipodean Pharmaceuticals, Inc.

San Francisco, California, United Statesbloomberg.com ↗

Ownership: Private
Development stage: Other

Overview

Completed enrollment in Phase 2 study for MitoQ in Parkinson's disease with 128 patients in New Zealand and Australia. The randomized, double-blind multi-center clinical trial compared MitoQ at 40 mg and 80 mg to placebo, with the primary endpoint being disease progression according to the Unified Parkinson's Disease Rating Scale[7].

Therapeutic areas: Neurology
Modalities: Small moleculesantioxidants
Industry: Biotech

Beyond the preview

Go deeper on Antipodean Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antipodean Pharmaceuticals, Inc..

Explore the full profile